$TWST

Laponis Adam sold $226K of TWST

Laponis Adam (Chief Financial Officer) sold 2,399 shares of Twist Bioscience Corp (TWST) at $94.33 ($0.23M total) on 2026-07-09.

Original reporting
SEC EDGAR · Laponis Adam
Published Jul 13, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

This provides incremental sentiment information (insider selling) but does not introduce new company fundamentals such as earnings, guidance, trials, or contracts.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing does not disclose motivations, remaining vesting/compensation context, or whether other insiders sold/bought around the same period.

Relevance 4/10Novelty 3/10Timing: new Form 4 filed 2026-07-13, covering sale dated 2026-07-09

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience, reported by its CFO.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

SEC Form 4 shows CFO Laponis Adam sold 2,399 shares of Twist Bioscience at $94.3340 on 2026-07-09.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a primary-source Form 4, but it is an open-market sale by an officer and does not include new operating, regulatory, or financial guidance.

Market effects

Minimal read-across to biotech tools/biomanufacturing peers; this is company-specific insider activity.

No clear regional spillover expected from a single officer sale disclosure.

Limited global relevance; no deal, trial, or regulatory action mentioned.

Counterpoint

Insider sales can be planned for liquidity or tax needs; absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Laponis Adam

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.